Case Study: Treating HER2-Positive MBC, Part II
Published Online: Tuesday, August 20, 2013
For High-Definition, ClickIn the continuation of a case-based discussion, the panel reviews clinical trials looking at potential treatment strategies for a 59 year-old woman with metastatic breast cancer (MBC). In the case study, the patient was diagnosed with ER and HER2-positive MBC and received adjuvant Adriamycin plus Cytoxan followed by paclitaxel with trastuzumab and 5 years of anastrozole. After 8 years, the patient recurred with pulmonary and liver metastases.
Andrew D. Seidman, MD, comments that the treatment recommended by Sara Hurvitz, MD, in part I was provocative and counterintuitive. In this segment, Hurvitz recommended administering a taxane with pertuzumab and trastuzumab in the frontline followed by HER2-targeted therapies alone with the potential to add an endocrine therapy. More data will be available on this treatment approach from the phase II PERTAIN trial, Seidman notes.
In regard to the chemotherapy utilized, Seidman references the HERNATA trial that compared trastuzumab plus docetaxel or vinorelbine as a frontline treatment for HER2-positive MBC. In this trial, both treatment approaches resulted in similar efficacy with significantly less toxicity in the vinorelbine arm, notes Edith A. Perez, MD.
Building off the HERNATA and CLEOPATRA trial, the phase II VELVET trial is exploring the combination of pertuzumab, trastuzumab, and vinorelbine for the first-line treatment of patients with HER2-positive MBC, Perez notes. In the first cohort of the trial, each treatment will be administered sequentially. In the second cohort, vinorelbine will be followed by simultaneous trastuzumab and pertuzumab. Results from the first cohort are expected to be presented at the 2013 San Antonio Breast Cancer Symposium.
In regard to chemotherapy, remarks Hope S. Rugo, MD, one nice thing about vinorelbine is the lack of alopecia. However, it is important to monitor gastrointestinal toxicities. Another treatment option, if approved in this space, could be treatment with T-DM1, Rugo suggests.
View More From This Discussion
Sara Hurvitz, MDAssistant Professor & Director,
Hematology/Oncology Breast Cancer Program, UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, California
Joyce A. O’Shaughnessy, MDCo-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology, PA/US Oncology,
Edith A. Perez, MDDeputy Director of the Mayo Clinic Cancer Center, Director of the Breast Cancer Translational Genomics Program and the Breast Program at Mayo Clinic,
Hope S. Rugo, MDProfessor of Medicine and Director of the Breast Oncology, Clinical Trials, and Education Program, University of California San Francisco Comprehensive Cancer Center, San Francisco, California
Andrew D. Seidman, MDProfessor of Medicine, Weill Cornell Cancer Center, Attending Physician at Memorial Sloan Kettering Cancer Center,
New York, New York
Most Popular Right Now
Online CME Activities
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.